- Home
- VTAK
as 07-26-2024 4:00pm EST
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | FORT MILL |
| Market Cap: | 2.6M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 76.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.58 - $8.40 | Next Earning Date: | 05-06-2024 |
| Revenue: | $439,000 | Revenue Growth: | 387.78% |
| Revenue Growth (this year): | 637.1% | Revenue Growth (next year): | 177.13% |
Stock Insider Trading Activity of Catheter Precision Inc. (VTAK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 22 '24 | Buy | $0.43 | 9,528 | $4,092.28 | 320,328 | SEC Form 4 |
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 22 '24 | Buy | $0.60 | 9,528 | $5,693.93 | 329,856 | SEC Form 4 |
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 18 '24 | Buy | $0.41 | 8,470 | $3,491.33 | 302,330 | SEC Form 4 |
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 18 '24 | Buy | $0.42 | 8,470 | $3,594.67 | 310,800 | SEC Form 4 |
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 16 '24 | Buy | $0.39 | 7,793 | $3,009.66 | 285,390 | SEC Form 4 |
| JENKINS DAVID A | VTAK | Executive Chairman and CEO | Jan 16 '24 | Buy | $0.39 | 8,470 | $3,313.46 | 293,860 | SEC Form 4 |
Latest Catheter Precision Inc. News
VTAK Breaking Stock News: Dive into VTAK Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 days ago
Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study
ACCESSWIRE
11 days ago
Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
ACCESSWIRE
12 days ago
Catheter Precision, Inc. Announces Effectiveness of 1-for-10 Reverse Stock Split
ACCESSWIRE
a month ago
Catheter Precision, Inc. Announces Receipt of First Purchase Order for VIVO from Distributor in Middle East
ACCESSWIRE
a month ago
Catheter Precision, Inc. Announces Receipt of LockeT Purchase Order for Eisenhower Medical Center, a Third California Hospital
ACCESSWIRE
2 months ago
Catheter Precision, Inc. (NYSE: VTAK) Announces Initial Orders from Ronald Reagan UCLA Medical Center and Rady Children’s Hospital in San Diego for LockeT
ACCESSWIRE
3 months ago
Catheter Precision, Inc. (VTAK) Announces Receipt of New Purchase Order and Product Evaluation at New Hospital
ACCESSWIRE
3 months ago
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report
Compare VTAK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTAK Catheter Precision Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.